Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1994 Sep;39(3):193-7.
doi: 10.1007/BF01533386.

Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients

A Boiardi  1 , A Silvani, P A Ruffini, L Rivoltini, G Parmiani, G Broggi, A Salmaggi
Affiliations
Clinical Trial

Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients

A Boiardi et al. Cancer Immunol Immunother. 1994 Sep.

Abstract

Nine patients with recurrent glioblastoma were given autologous adherent lymphokine-activated killer (A-LAK) cells and interleukin-2 (IL-2) administered directly into the tumor cavity through an Ommaya tube placed during surgery/biopsy. The immunotherapy was well tolerated and the response rate was 33% (one complete response, two partial responses, four with stable disease and two with progressive disease). However, survival 18 months from initial diagnosis did not differ from that reported in the literature for patients treated conventionally. Serial determinations of IL-2 in the tumor cavity during the course of treatment revealed that IL-2 concentrations were sufficient to maintain lymphocyte activation. Since steroid medication was discontinued during treatment and A-LAK cells have greater antitumor activity than standard LAK cells, other factors are discussed that might explain the limited results.

PubMed Disclaimer

References

    1. Burger PC, Boyko OB. The pathology of the central nervous system radiation injury. In: Gutin PH, Leibel SA, Sheline GE, editors. Radiation injury to the nervous system. New York: Raven Press; 1991. p. 236.
    1. Chocair AK, Levin VA, Gutin PH, Davis RL, Silver P, Edwards MSB, Wilson CB. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg. 1986;65:654. - PubMed
    1. Denicoff KD, Rubinov DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosestein D, Rosenberg SA. The neuropsychiatric effects of the treatment with interleukin-2 and lymphokine-activated killer cells. Ann Int Med. 1987;107:293. - PubMed
    1. Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978;120:2027. - PubMed
    1. Gutin PH, Leibel SA, Wara WM, Chouchair A, Levin VA, Philips TL, Silver P, Da Silva V, Edwards MSB, Davis RL, Weaver KA, Lamb S. Recurrent malignant gliomas: Survival following interstitial brachitherapy with high-activity iodine-124 sources. J Neurosurg. 1987;67:864. - PubMed

Publication types

LinkOut - more resources